The Hindu Business Line : USFDA clearance for Sun Pharma plants

SUN Pharma's plans for the world's largest generic drugs market, the US, has received a fillip with two of its factories receiving a clearance from the US regulatory authorities.

The company's bulk actives plant at Panoli, that manufactures the ingredients that go into medicines and tablet-making plant at Halol were inspected and cleared by the US-Food and Drug Administration (USFDA), the company said on Wednesday.

With the recent approvals, Sun Pharma now has a total of three factories that are ready to manufacture for the US, including its Ahmednagar site.

For Sun's Panoli factory, the USFDA approval is the second international clearance, the first being from the European regulatory authorities. Europe-based innovator companies have been sourcing from this plant, the company communiqué said.

More Stories on : Announcements | Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Delays hit clinical trials of India-specific AIDS vaccine

USFDA clearance for Sun Pharma plants

Balaji Tele to boost regional sponsored programmes

Hewitt to include blue-collar workers in `Best Employer' survey

Alstom India bags Renusagar's Rs 70-cr upgrade order

`Investor protection to be vital part of Companies Act'

Bombay HC okays cut in VSNL premium account

Blue Star bags Rs 9-cr order for Delhi airport

Thermax to buy out minority stake in Babcock joint venture — Sales up at Rs 603.81 cr

Schwing Stetter to double capacity

GMR Ind profit up 276 pc; plans Rs 60-cr expansion

Orchid inks deal with Par for US marketing

Abhinav Outsourcing in tie-up with Canadian varsities

Suryalakshmi Cotton plans expansion

Pvt firms top in PSU debt placements